Foghorn Therapeutics (FHTX) News Today $7.84 +0.12 (+1.55%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Foghorn Therapeutics to Participate in Three Upcoming Investor ConferencesNovember 12, 2024 | globenewswire.comAnalysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter ReportNovember 7, 2024 | finance.yahoo.comWhat is HC Wainwright's Forecast for FHTX FY2024 Earnings?Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Analysts at HC Wainwright raised their FY2024 earnings estimates for Foghorn Therapeutics in a research report issued to clients and investors on Tuesday, November 5th. HC Wainwright analyst A. Fein now expects that the company will post earNovember 7, 2024 | marketbeat.comWhat is Wedbush's Estimate for FHTX FY2024 Earnings?Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Research analysts at Wedbush lifted their FY2024 EPS estimates for shares of Foghorn Therapeutics in a report issued on Monday, November 4th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($1.57) per share for the yearNovember 7, 2024 | marketbeat.comFoghorn Therapeutics Reports Third Quarter HighlightsNovember 6, 2024 | markets.businessinsider.comOptimistic Buy Rating for Foghorn Therapeutics Amid Promising Phase 1 Study and Strategic Pipeline AdvancementsNovember 6, 2024 | markets.businessinsider.comFoghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate UpdateNovember 4, 2024 | globenewswire.comShort Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Increases By 9.1%Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,200,000 shares, an increase of 9.1% from the September 15th total of 1,100,000 shares. Based on an average daily volume of 152,000 shares, the short-interest ratio is presently 7.9 days. Currently, 4.2% of the shares of the stock are sold short.October 17, 2024 | marketbeat.comFoghorn Therapeutics Unveils Clinical Pipeline ProgressOctober 11, 2024 | finance.yahoo.comFoghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid TumorsOctober 10, 2024 | globenewswire.comFoghorn Therapeutics (NASDAQ:FHTX) Stock, Short Interest ReportOctober 8, 2024 | benzinga.comFoghorn Therapeutics (NASDAQ:FHTX) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comFoghorn Therapeutics to Participate in the BMO Oncology SummitOctober 1, 2024 | globenewswire.comPerceptive Advisors LLC Purchases Shares of 544,000 Foghorn Therapeutics Inc. (NASDAQ:FHTX)Perceptive Advisors LLC acquired a new position in shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 544,000 shares of the company's stock, valueSeptember 30, 2024 | marketbeat.comDeerfield Management Company L.P. Series C Purchases Shares of 2,518,500 Foghorn Therapeutics Inc. (NASDAQ:FHTX)Deerfield Management Company L.P. Series C acquired a new position in shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,518,500 shaSeptember 26, 2024 | marketbeat.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Insider Sells $358,990.24 in StockSeptember 25, 2024 | insidertrades.comFoghorn Therapeutics: Holding for FHD-286 Clinical Trial Outcomes and Financial Position AnalysisSeptember 24, 2024 | markets.businessinsider.comFoghorn Therapeutics (NASDAQ:FHTX) PT Raised to $9.00 at Morgan StanleyMorgan Stanley upped their price target on Foghorn Therapeutics from $6.00 to $9.00 and gave the company an "equal weight" rating in a research report on Tuesday.September 24, 2024 | marketbeat.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Sees Large Increase in Short InterestFoghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) saw a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 1,060,000 shares, an increase of 65.0% from the August 15th total of 642,400 shares. Currently, 3.7% of the company's shares are sold short. Based on an average trading volume of 121,600 shares, the days-to-cover ratio is presently 8.7 days.September 13, 2024 | marketbeat.comFoghorn Therapeutics (NASDAQ:FHTX) Sees Large Volume IncreaseFoghorn Therapeutics (NASDAQ:FHTX) Sees Large Volume IncreaseSeptember 13, 2024 | marketbeat.comInsider Sale: Chief Scientific Officer Steven Bellon Sells 20,000 Shares of Foghorn ...September 11, 2024 | finance.yahoo.comFoghorn Therapeutics (NASDAQ:FHTX) Reaches New 12-Month High at $9.22Foghorn Therapeutics (NASDAQ:FHTX) Hits New 1-Year High at $9.22September 9, 2024 | marketbeat.comJefferies Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy RecommendationSeptember 5, 2024 | msn.comJefferies Financial Group Initiates Coverage on Foghorn Therapeutics (NASDAQ:FHTX)Jefferies Financial Group initiated coverage on Foghorn Therapeutics in a research note on Tuesday. They issued a "buy" rating and a $18.00 target price for the company.September 3, 2024 | marketbeat.comFoghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business OfficerSeptember 3, 2024 | globenewswire.comFoghorn Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberAugust 28, 2024 | globenewswire.comRaymond James & Associates Purchases 107,967 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX)Raymond James & Associates raised its position in Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) by 4.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,338,423 shares of the company's stoAugust 24, 2024 | marketbeat.comFoghorn Therapeutics Inc. (FHTX)August 24, 2024 | finance.yahoo.comFoghorn Therapeutics Inc Ordinary SharesAugust 21, 2024 | morningstar.comEvercore ISI Group Initiates Coverage of Foghorn Therapeutics (FHTX) with Outperform RecommendationAugust 20, 2024 | msn.comFoghorn Therapeutics (NASDAQ:FHTX) Research Coverage Started at Evercore ISIEvercore ISI initiated coverage on Foghorn Therapeutics in a research report on Monday. They issued an "outperform" rating and a $20.00 target price for the company.August 19, 2024 | marketbeat.comFoghorn Therapeutics Inc. Expected to Earn Q3 2024 Earnings of ($0.42) Per Share (NASDAQ:FHTX)Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Stock analysts at HC Wainwright upped their Q3 2024 earnings estimates for shares of Foghorn Therapeutics in a research report issued on Monday, August 12th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($0.42) peAugust 15, 2024 | marketbeat.comFoghorn Therapeutics Drug Candidates FHD-286 and FHD-909 Show Promise in Early Trials, Justifying Buy RatingAugust 12, 2024 | markets.businessinsider.comWedbush Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)August 10, 2024 | markets.businessinsider.comFoghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate UpdateAugust 8, 2024 | globenewswire.comJacobs Levy Equity Management Inc. Raises Stock Holdings in Foghorn Therapeutics Inc. (NASDAQ:FHTX)Jacobs Levy Equity Management Inc. grew its stake in shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) by 101.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 216,270 shares of the companyAugust 2, 2024 | marketbeat.comInstitutional investors own a significant stake of 36% in Foghorn Therapeutics Inc. (NASDAQ:FHTX)July 29, 2024 | finance.yahoo.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Short Interest UpdateFoghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 1,260,000 shares, a growth of 15.6% from the June 30th total of 1,090,000 shares. Based on an average daily trading volume, of 102,900 shares, the days-to-cover ratio is presently 12.2 days. Currently, 4.0% of the company's stock are short sold.July 29, 2024 | marketbeat.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Short Interest Up 10.6% in JuneFoghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 1,090,000 shares, an increase of 10.6% from the June 15th total of 985,300 shares. Based on an average daily trading volume, of 102,700 shares, the short-interest ratio is currently 10.6 days. Currently, 3.5% of the company's stock are sold short.July 16, 2024 | marketbeat.comFoghorn Therapeutics to Participate in Upcoming Investor Conferences in JuneMay 28, 2024 | globenewswire.comFoghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance PipelineMay 22, 2024 | globenewswire.comFoghorn prices $110M mixed-shelf registered direct offeringMay 20, 2024 | msn.comFoghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded WarrantsMay 20, 2024 | globenewswire.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price TargetMay 9, 2024 | finance.yahoo.comHC Wainwright Analysts Decrease Earnings Estimates for Foghorn Therapeutics Inc. (NASDAQ:FHTX)Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Equities research analysts at HC Wainwright cut their Q3 2024 earnings per share estimates for shares of Foghorn Therapeutics in a report released on Tuesday, May 7th. HC Wainwright analyst A. Fein now anticipates that the company will earnMay 9, 2024 | marketbeat.comBrokers Offer Predictions for Foghorn Therapeutics Inc.'s Q1 2025 Earnings (NASDAQ:FHTX)Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Research analysts at Wedbush issued their Q1 2025 earnings estimates for shares of Foghorn Therapeutics in a report released on Monday, May 6th. Wedbush analyst R. Driscoll anticipates that the company will post earnings per share of ($0.36)May 8, 2024 | marketbeat.comBuy Rating Affirmed on Foghorn Therapeutics with Promising AML Drug Pipeline and Broad Market PotentialMay 7, 2024 | markets.businessinsider.comFoghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 7, 2024 | finance.yahoo.comFoghorn Therapeutics' (FHTX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Foghorn Therapeutics in a research report on Tuesday.May 7, 2024 | marketbeat.comFoghorn Therapeutics, Inc.: Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate UpdateMay 6, 2024 | finanznachrichten.de Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. FHTX Media Mentions By Week FHTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FHTX News Sentiment▼0.000.49▲Average Medical News Sentiment FHTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FHTX Articles This Week▼01▲FHTX Articles Average Week Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies C4 Therapeutics News Today Arvinas News Today Xencor News Today Recursion Pharmaceuticals News Today Galapagos News Today Immunocore News Today Nurix Therapeutics News Today Cassava Sciences News Today Kiniksa Pharmaceuticals News Today Travere Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FHTX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
